Home > Knowledge > Content

What are the effects of Alpha Lipoic Acid powder on diabetic patients?

Feb 17, 2022

1. Improving diabetic peripheral neuropathy

One of the pathogenesis of diabetic neuropathy is the increase of oxidative stress. Therefore, a lot of research has been done on the potential antioxidants to reduce oxidative stress, improve the pathophysiological process of neuropathy and relieve pain.

It has been confirmed by several prospective placebo-controlled studies Efficacy of alpha-lipoic acid powder for symptomatic diabetic neuropathy. For example, the SYDNEY1 study showed a reduction in pain, cutaneous paresthesia, and numbness with three consecutive weeks of daily intravenous ala injections. In the SYDNEY2 study, 181 diabetic patients with distal symmetric polyneuropathy were randomized into four groups to receive 5-week oral ala 600 mg, 1200 mg, 1800 mg, and placebo. The results show that different doses of ALA reduce symptoms of neuropathy, including tingling, burning pain, paresthesia, and numbness, compared with placebo. The findings showed that the efficacy of ALA was independent of the dose it was used; The most desirable dose of ala to use is 600 mg, as higher doses do not increase efficacy but rather tend to increase side effects, including nausea, vomiting, and vertigo, among others.

alpha lipoic acid powder

Therefore, based on the available scientific studies, symptomatic diabetic neuropathy patients can be Alpha Lipoic acid powder to help treat diabetic polyneuropathy, especially in those patients for whom antidepressant (e.g., amitriptyline, duloxetine, venlafaxine) or patients for whom anticonvulsant medications (e.g., pregabalin) were ineffective or not tolerated.

2. Blocking diabetic glycosylation

Alpha Lipoic acid powder also blocks the process of glycosylation (the combination of glucose and protein) in diabetes, which is an important cause of damage to the organism. It makes blood glucose more stable, markedly increases the sensitivity of diabetic affected cells to insulin, increases ATP production in the cellular energy cycle, and ameliorates the cardiomyopathy complicated by diabetes. Moreover, adjunctive therapies are indicated for comorbid arteriosclerosis, cataracts, fatty liver, and others in patients with diabetes.

Related Industry Knowledge